<?xml version='1.0' encoding='utf-8'?>
<document id="18154477"><sentence text="Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus."><entity charOffset="43-56" id="DDI-PubMed.18154477.s1.e0" text="fosamprenavir" /></sentence><sentence text="To evaluate the pharmacokinetic compatibility of a ritonavir-boosted indinavir-fosamprenavir combination among patients with human immunodeficiency virus (HIV)"><entity charOffset="51-60" id="DDI-PubMed.18154477.s2.e0" text="ritonavir" /><entity charOffset="69-78" id="DDI-PubMed.18154477.s2.e1" text="indinavir" /><entity charOffset="79-92" id="DDI-PubMed.18154477.s2.e2" text="fosamprenavir" /><pair ddi="false" e1="DDI-PubMed.18154477.s2.e0" e2="DDI-PubMed.18154477.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18154477.s2.e0" e2="DDI-PubMed.18154477.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s2.e0" e2="DDI-PubMed.18154477.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18154477.s2.e1" e2="DDI-PubMed.18154477.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s2.e1" e2="DDI-PubMed.18154477.s2.e2" /></sentence><sentence text="" /><sentence text="Single-center, nonrandomized, prospective, multiple-dose, two-phase pharmacokinetic study" /><sentence text="" /><sentence text="University research center" /><sentence text="" /><sentence text="Eight adult patients with HIV infection who had been receiving and tolerating indinavir 800 mg-ritonavir 100 mg twice/day for at least 2 weeks"><entity charOffset="78-87" id="DDI-PubMed.18154477.s8.e0" text="indinavir" /></sentence><sentence text=" Intervention" /><sentence text=" After 12-hour pharmacokinetic sampling was performed on all patients (period A), fosamprenavir (a prodrug of amprenavir) 700 mg twice/day was coadministered for 5 days, with a repeat 12-hour pharmacokinetic sampling performed on the fifth day (period B)"><entity charOffset="82-95" id="DDI-PubMed.18154477.s10.e0" text="fosamprenavir" /><entity charOffset="110-120" id="DDI-PubMed.18154477.s10.e1" text="amprenavir" /><pair ddi="false" e1="DDI-PubMed.18154477.s10.e0" e2="DDI-PubMed.18154477.s10.e0" /><pair ddi="false" e1="DDI-PubMed.18154477.s10.e0" e2="DDI-PubMed.18154477.s10.e1" /></sentence><sentence text="" /><sentence text="Pharmacokinetic parameters were determined for indinavir, ritonavir, and amprenavir: area under the concentration-time curve from time 0 to 12 hours after dosing (AUC(0-12)), maximum plasma concentration (C(max)), and 12-hour plasma concentration (C(12))"><entity charOffset="47-56" id="DDI-PubMed.18154477.s12.e0" text="indinavir" /><entity charOffset="58-67" id="DDI-PubMed.18154477.s12.e1" text="ritonavir" /><entity charOffset="73-83" id="DDI-PubMed.18154477.s12.e2" text="amprenavir" /><pair ddi="false" e1="DDI-PubMed.18154477.s12.e0" e2="DDI-PubMed.18154477.s12.e0" /><pair ddi="false" e1="DDI-PubMed.18154477.s12.e0" e2="DDI-PubMed.18154477.s12.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s12.e0" e2="DDI-PubMed.18154477.s12.e2" /><pair ddi="false" e1="DDI-PubMed.18154477.s12.e1" e2="DDI-PubMed.18154477.s12.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s12.e1" e2="DDI-PubMed.18154477.s12.e2" /></sentence><sentence text=" For each parameter, the geometric mean, as well as the geometric mean ratio (GMR) comparing period B with period A, were calculated" /><sentence text=" Indinavir C(max) was lowered by 20% (GMR 0" /><sentence text="80, 95% confidence interval [CI] 0" /><sentence text="67-0" /><sentence text="96), AUC(0-12) was lowered by 6% (GMR 0" /><sentence text="94, 95% CI 0" /><sentence text="74-1" /><sentence text="21), and C(12) was increased by 28% (GMR 1" /><sentence text="28, 95% CI 0" /><sentence text="78-2" /><sentence text="10)" /><sentence text=" Ritonavir AUC(0-12) was 20% lower (GMR 0" /><sentence text="80, 95% CI 0" /><sentence text="54-1" /><sentence text="19), C(max) was 15% lower (GMR 0" /><sentence text="85, 95% CI 0" /><sentence text="55-1" /><sentence text="32), and C(12) was 7% lower (GMR 0" /><sentence text="93, 95% CI 0" /><sentence text="49-1" /><sentence text="76)" /><sentence text=" With the exception of indinavir C(max), the changes in indinavir and ritonavir pharmacokinetic parameters observed after fosamprenavir coadministration were not statistically significant"><entity charOffset="56-65" id="DDI-PubMed.18154477.s34.e0" text="indinavir" /><entity charOffset="70-79" id="DDI-PubMed.18154477.s34.e1" text="ritonavir" /><entity charOffset="122-135" id="DDI-PubMed.18154477.s34.e2" text="fosamprenavir" /><pair ddi="false" e1="DDI-PubMed.18154477.s34.e0" e2="DDI-PubMed.18154477.s34.e0" /><pair ddi="false" e1="DDI-PubMed.18154477.s34.e0" e2="DDI-PubMed.18154477.s34.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s34.e0" e2="DDI-PubMed.18154477.s34.e2" /><pair ddi="false" e1="DDI-PubMed.18154477.s34.e1" e2="DDI-PubMed.18154477.s34.e1" /><pair ddi="false" e1="DDI-PubMed.18154477.s34.e1" e2="DDI-PubMed.18154477.s34.e2" /></sentence><sentence text=" The geometric means of amprenavir AUC(0-12), C(max), and C(12) were 41,517 ng*hour/ml (95% CI 30,317-56,854 ng*hr/ml), 5572 ng/ml (95% CI 4330-7170 ng/ml), and 2421 ng/ml (95% CI 1578-3712 ng/ml), respectively" /><sentence text="" /><sentence text="The combination of indinavir 800 mg-ritonavir 100 mg-fosamprenavir 700 mg twice/day appears to be devoid of a clinically significant drug-drug interaction and should be evaluated as an alternative regimen in salvage HIV treatment"><entity charOffset="19-28" id="DDI-PubMed.18154477.s37.e0" text="indinavir" /><entity charOffset="53-66" id="DDI-PubMed.18154477.s37.e1" text="fosamprenavir" /><pair ddi="false" e1="DDI-PubMed.18154477.s37.e0" e2="DDI-PubMed.18154477.s37.e0" /><pair ddi="false" e1="DDI-PubMed.18154477.s37.e0" e2="DDI-PubMed.18154477.s37.e1" /></sentence><sentence text=" This combination may be suitable as part of a background regimen to optimize the therapeutic benefit of newer classes of antiretroviral agents such as the integrase and coreceptor inhibitors in the treatment of multidrug-resistant viruses" /><sentence text="" /></document>